✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Comparison

Ozempic vs Mounjaro

Released: Last reviewed:

Ozempic vs Mounjaro: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.

Side-by-sideTrial-cited
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Comparison: Ozempic vs Mounjaro

Both are reviewed at American Telehealth Review against published clinical evidence and FDA labeling.

Key differentiators

Other comparisons

All comparisons →

Key facts, checked November 20, 2026

Both are FDA-approved for type 2 diabetes, not for weight management. The Ozempic injection label (semaglutide) also covers lowering cardiovascular risk and, after FLOW (NEJM 2024), slowing kidney decline in adults with type 2 diabetes and kidney disease. The Mounjaro label (tirzepatide) covers blood-sugar control in adults and children 10 and older. Their weight-management counterparts are Wegovy and Zepbound. In SURMOUNT-5 (NEJM 2025), adults without diabetes lost 20.2% on tirzepatide versus 13.7% on semaglutide at 72 weeks. FDA’s November 9, 2026 safety communication adds a NAION warning to both labels.